News

Screening for Oesophageal cancer, PromarkerEso – Healthy Living, 2GB

Dr Richard Lipscombe, Managing Director of Proteomics International (ASX:PIQ), spoke with 2GB’s Healthy Living hosts, Dr Ginni Mansberg and Ned Green on January 14th,  2023. The discussion centred around Proteomics International’s prototype diagnostic blood test for oesophageal cancer, known as PromarkerEso.

Oesophageal cancer is the 7th most common cancer globally and is currently diagnosed through an endoscopy with biopsy, often leading to diagnosis in later stages. PromarkerEso uses blood biomarkers – protein ‘fingerprints’ – to diagnose oesophageal adenocarcinoma and the pre-malignant condition, Barrett’s oesophagus with the goal to detect disease early, potentially improving health outcomes.

You can listen to the discussion from the 1hr 10min mark – Healthy Living – January 14th (2gb.com)

Subscribe

  • This field is for validation purposes and should be left unchanged.